TITLE

Expert comments

AUTHOR(S)
Mandhani, Anil
PUB. DATE
June 2006
SOURCE
Indian Journal of Urology;Jun2006, Vol. 22 Issue 2, p134
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Presents the author's views on the safety and effectiveness of the Dutasteride in the treatment of urinary retention. Comparison between the effectiveness of Dutasteride and Finasteride; Improvement of symptoms in patients administered with placebo treatments;
ACCESSION #
21712698

 

Related Articles

  • Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer. Thompson, Ian M.; Chen Chi; Ankerst, Donna Pauler; Goodman, Phyllis J.; Tangen, Catherine M.; Lippman, Scott M.; Lucia, M. Scott; Parnes, Howard L.; Coliman Jr., Charles A. // JNCI: Journal of the National Cancer Institute;8/16/2006, Vol. 98 Issue 16, p1128 

    Background: In the Prostate Cancer Prevention Trial (PCPT), men receiving finasteride had a 24.8% lower risk of prostate cancer than men receiving placebo but a higher risk of high-grade cancer. We examined the impact of finasteride on the sensitivity and area under the receiver operating...

  • Prostate Cancer.  // Annals of Internal Medicine;9/21/2004, Vol. 141 Issue 6, p457 

    This article briefly reports a study investigating the effectiveness of finasteride, tumor-suppresive agent, in preventing or delaying the appearance of prostate cancer. Finasteride inhibits 5-α-reductase, an enzyme that converts testosterone to dihydrotestosterone, the primary androgen in...

  • The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials -- A secondary analysis. Walach, Harald; Sadaghiani, Catarina; Dehm, Cornelia; Bierman, Dick // BMC Medical Research Methodology;2005, Vol. 5, p26 

    Background and purpose: Placebo response rates in clinical trials vary considerably and are observed frequently. For new drugs it can be difficult to prove effectiveness superior to placebo. It is unclear what contributes to improvement in the placebo groups. We wanted to clarify, what elements...

  • Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation. Wade, Alan G.; Crawford, Gordon M.; Pumford, Neil; Koscielny, Volker; Maycock, Susan; McConnachie, Alex // BMC Medical Research Methodology;2011, Vol. 11 Issue 1, p91 

    Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis (JIA). Limited data from the patients' perspective...

  • QRXPHARMA BEGINS PHASE III CLINICAL TRIAL FOR PAIN THERAPY.  // Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p1 

    The article reports on the Phase III clinical trial conducted by QRxPharma for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy. The trial involved a double-blind, placebo-controlled study that aims to compare the efficacy and safety of four different dosage...

  • A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. Salvatorelli, Nicola; García-Larrosa, alejandro; allegrini, alessandro; Pavone, Daniele // Urologia Internationalis;Oct2016, Vol. 97 Issue 3, p347 

    Objective: To assess the efficacy and safety of a new medical device (MD; a capsule whose main component is a crosslinked protein) in the prevention of uncomplicated cystitis recurrences. Methods: Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture...

  • Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p67 

    The article reports on the results of the Toviaz, fesoterodine fumarate, Study A0221048 by Pfizer Inc. The study aims to determine the effectiveness and safety of a flexible dose regimen for patients with overactive bladder including nocturnal urinary urgency. It also reveals that treatment with...

  • Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. Chu, Jennifer; Sloan, Caroline E.; Freedberg, Kenneth A.; Yazdanpanah, Yazdan; Losina, Elena // AIDS Research & Therapy;2011, Vol. 8, p14 

    Background: Our goal was to illustrate a method for making indirect treatment comparisons in the absence of head-to-head trials, by portraying the derivation of published efficacies for prophylaxis regimens of HIV-related opportunistic infections. Results: We identified published results of...

  • Doxazosin plus finasteride reduced clinical progression of benign prostatic hyperplasia more than either drug used alone. Hoffman, Richard // ACP Journal Club;Jul/Aug2004, Vol. 141 Issue 1, p20 

    Doxazosin plus finasteride reduced clinical progression of benign prostatic hyperplasia more than either drug used alone. In men with benign prostatic hyperplasia, long-term doxazosin plus finasteride combination therapy reduced the risk for overall clinical progression of benign prostatic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics